ERBB2 and neoplasm: Bielamowicz et al. demonstrated improved anti-tumor efficacy in GBM models using trivalent CAR T-cells targeting ephrin A receptor 2, human epidermal growth factor receptor 2 (HER2) and interleukin-13 receptor alpha-2 (IL13Rα2) (30).